Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson's CAR-T Partner Legend Biotech Plans IPO

By Mark Prvulovic - Mar 10, 2020 at 5:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors should keep an eye out for the arrival of this biotech stock.

Johnson & Johnson (JNJ 1.13%) partner Legend Biotech is planning for a U.S. initial public offering. The company, which is owned by the Hong Kong-listed GenScript Biotech, has submitted a draft registration proposal to the U.S. Securities Exchange Commission (SEC), laying down the groundwork for an eventual IPO.

Legend Biotech was a relatively obscure company until its chimeric antigen receptor T cell (CAR-T) candidate showed impressive results in patients with multiple myeloma, a rare type of blood and bone marrow cancer. Back in 2017, when Legend first published its findings, its CAR-T candidate demonstrated a 100% response rate with a 94% clinical remission rate in a population of 35 drug-resistant patients.

A businessman holding a red arrow moving upwards with the letters IPO on stocks of coins.

Image source: Getty Images.

The results were so impressive that Johnson & Johnson decided to partner with Legend, paying $350 million in cash to help develop the program. Under the agreement, the pharmaceutical giant paid half of Legend's development costs in return for a 50% cut of all profits from international sales -- except in China, where GenScript Biotech would keep 70% of all profits. Legend's IPO filing is still confidential, so key details such as how much the biotech company intends to raise are anyone's guess at this point.

Understanding CAR-T Therapies

CAR-T therapies are a new type of cancer treatment, and they have shown promising results so far. Patients' T cells (an important type of cell in the immune system) are extracted from their blood and modified in a laboratory to better target cancer cells, then reinfused into the patient. Unfortunately, CAR-T therapies tend to be extremely expensive, costing as much as $475,000 for a round of treatment depending on the type of cancer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$179.52 (1.13%) $2.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.